Pesquisar um ensaio clínico
Outras opções de pesquisa
19 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Ensaio concluído = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Baden-Württemberg
HEIDELBERG
SOPHA: Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH
Thoraxklinik-Heidelberg gGmbH
Abteilung für Pneumologie und Beatmungsmedizin
ALEMANHA
Baden-Württemberg
HEIDELBERG
RIVER II: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Thoraxklinik-Heidelberg gGmbH
Abteilung für Pneumologie und Beatmungsmedizin
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
MACiTEPH: A Prospective, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Adaptive Phase 3 Study With Open-label Extension to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension - AT
Institution: Information not provided - AT
BELGICA
VLAAMS BRABANT
LEUVEN
Prospective, randomized, placebo-controlled, double-blind, multicenter, , 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension
UZ Leuven - Campus Gasthuisberg
Pneumology department
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
MACiTEPH: A Prospective, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Adaptive Phase 3 Study With Open-label Extension to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension -ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
MERIT-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, , 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension - US
Institution: Information not provided - US
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MERIT-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, , 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Institution: Information not provided - FR
JAPAO
JAPAN
NAGASAKI
A Prospective, Multicenter, Open-label, Single Arm, Phase III Study to Assess the Efficacy and Safety of Macitentan (ACT-064992) in Subjects With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Nagasaki University Hospital
Department of cardiovascular medicine
PORTUGAL
CENTRO
ADDRESS: NOT PROVIDED - PT
CHEST-1: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) (Phase III) - PT
Institution: Information not provided - PT
REINO UNIDO
Cambridgeshire
CAMBRIDGE
MERIT-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, , 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension - UK
Royal Papworth Hospital
Papworth Hospital
REPUBLICA CHECA
Capital City Prague
ADDRESS: NOT PROVIDED - CZ
CHEST-1: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) (Phase III) - CZ
Institution: Information not provided - CZ
Ensaio (s) clínico (s) multinacional (ais)
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial- coordination
Institution: Information not provided - DE
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (phase III)
Institution: Information not provided - GB
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (phase III)
Institution: Information not provided - GB
SUICA
Suisse Alémanique
ALLSCHWIL
MERIT-2: Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of Macitentan in subjects with Chronic Thromboembolic Pulmonary Hypertension (Phase II)
Actelion Pharmaceuticals Ltd.
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH
MERIT-1: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of Macitentan in subjects with inoperable Chronic Thromboembolic Pulmonary Hypertension (Phase II)
Institution: Information not provided - CH
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH